Suppr超能文献

外泌体对 COVID-19 的多种影响:从传播到治疗发展的进展视角。

Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments.

机构信息

Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul, South Korea.

出版信息

Front Immunol. 2021 Jul 28;12:716407. doi: 10.3389/fimmu.2021.716407. eCollection 2021.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain of coronavirus and the causative agent of the current global pandemic of coronavirus disease 2019 (COVID-19). There are currently no FDA-approved antiviral drugs for COVID-19 and there is an urgent need to develop treatment strategies that can effectively suppress SARS-CoV-2 infection. Numerous approaches have been researched so far, with one of them being the emerging exosome-based therapies. Exosomes are nano-sized, lipid bilayer-enclosed structures, share structural similarities with viruses secreted from all types of cells, including those lining the respiratory tract. Importantly, the interplay between exosomes and viruses could be potentially exploited for antiviral drug and vaccine development. Exosomes are produced by virus-infected cells and play crucial roles in mediating communication between infected and uninfected cells. SARS-CoV-2 modulates the production and composition of exosomes, and can exploit exosome formation, secretion, and release pathways to promote infection, transmission, and intercellular spread. Exosomes have been exploited for therapeutic benefits in patients afflicted with various diseases including COVID-19. Furthermore, the administration of exosomes loaded with immunomodulatory cargo in combination with antiviral drugs represents a novel intervention for the treatment of diseases such as COVID-19. In particular, exosomes derived from mesenchymal stem cells (MSCs) are used as cell-free therapeutic agents. Mesenchymal stem cell derived exosomes reduces the cytokine storm and reverse the inhibition of host anti-viral defenses associated with COVID-19 and also enhances mitochondrial function repair lung injuries. We discuss the role of exosomes in relation to transmission, infection, diagnosis, treatment, therapeutics, drug delivery, and vaccines, and present some future perspectives regarding their use for combating COVID-19.

摘要

严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)是一种新型冠状病毒,也是当前全球 2019 年冠状病毒病(COVID-19)大流行的病原体。目前,尚无 FDA 批准用于 COVID-19 的抗病毒药物,因此迫切需要开发能够有效抑制 SARS-CoV-2 感染的治疗策略。迄今为止,已经研究了许多方法,其中之一是新兴的外泌体治疗方法。外泌体是纳米大小的、双层脂质包裹的结构,与所有类型的细胞(包括呼吸道细胞)分泌的病毒具有结构相似性。重要的是,外泌体与病毒之间的相互作用可能被用于开发抗病毒药物和疫苗。病毒感染细胞会产生外泌体,并在调节感染细胞和未感染细胞之间的通讯方面发挥关键作用。SARS-CoV-2 会调节外泌体的产生和组成,并可利用外泌体的形成、分泌和释放途径来促进感染、传播和细胞间扩散。外泌体已被用于治疗各种疾病(包括 COVID-19)患者的治疗益处。此外,用载有免疫调节货物的外泌体联合抗病毒药物给药代表了治疗 COVID-19 等疾病的新干预措施。特别是,源自间充质干细胞(MSCs)的外泌体被用作无细胞治疗剂。间充质干细胞衍生的外泌体可减少细胞因子风暴并逆转与 COVID-19 相关的宿主抗病毒防御抑制作用,还可增强线粒体功能修复肺损伤。我们讨论了外泌体在传播、感染、诊断、治疗、治疗学、药物传递和疫苗方面的作用,并提出了一些关于将其用于抗击 COVID-19 的未来展望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e22c/8355618/7985a839f09c/fimmu-12-716407-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验